Skip to main content

Table 2 Correlations of DR with clinicopathologic features

From: Peritumoral ductular reaction: a poor postoperative prognostic factor for hepatocellular carcinoma

  DR (<2 vs ≥2)
Variable   Low (%) High (%) p
Age (year) (median; 25 and 75 percentiles) 50; 40-59 ≤50 13 (50.0) 43 (53.8) 0.379
>50 13 (50.0) 37 (46.2)
Gender   Male 22 (84.6) 66 (82.5) 0.534
Female 4 (15.4) 14 (17.5)
ALT (U/L) (median; 25 and 75 percentiles) 44.6; 29.9-72 ≤40 16 (61.5) 28 (35.0) 0.017
>40 10 (38.5) 52 (65.0)
γ-GT (U/L) (median; 25 and 75 percentiles) 74.6; 46.4-106.8 ≤55 13 (50.0) 24 (30.0) 0.063
>55 13 (50.0) 56 (70.0)
ALP (U/L) (median; 25 and 75 percentiles) 145; 116.5-190 ≤121 13 (50.0) 18 (22.5) 0.007
>121 13 (50.0) 62 (77.5)
AFP (ng/ml) (median; 25 and 75 percentiles) 325; 40.9-1000 ≤20 11 (42.3) 14 (17.5) 0.010
>20 15 (57.7) 66 (82.5)
HBsAg state   Negative 10 (38.5) 6 (7.5) 4.9E-04
Positive 16 (61.5) 74 (92.5)
Tumor size (cm) (median; 25 and 75 percentiles) 7; 4.6-11.8 ≤5 7 (26.9) 28 (35.0) 0.447
>5 19 (73.1) 52 (65.0)
Tumor number   Single 25 (96.2) 54 (67.5) 0.004
Multiple 1 (3.8) 26 (32.5)
Tumor capsule   Yes 10 (38.5) 14 (17.5) 0.027
None 16 (61.5) 66 (82.5)
Vascular invasion   No 18 (69.2) 52 (65.0) 0.692
Yes 8 (30.8) 28 (35.0)
Microscopic vascular invasion (mean ± SD)* 4.3 ± 3.5 ≤5 7 (87.5) 10 (35.7) 0.031
>5 1 (12.5) 18 (64.3)
BCLC stage (A/B/C) 39/12/55 A 16 (61.5) 23 (28.8) 0.003
B/C 10 (38.5) 57 (71.2)
TNM stage (I/II/III) 35/23/48 I 15 (57.7) 20 (25.0) 0.002
II/III 11 (42.3) 60 (75.0)
Recurrence**   Early 8 (47.1) 52 (65.0) 0.010
   Late 9 (52.9) 12 (35.0)  
  1. Chi-square tests for all the analyses. *Vascular invasion positive cases (36) were enrolled, the degree of microscopic peritumoral vascular invasion was observed. **A total of 81/106 (76.4%) patients suffered from tumor recurrence, of whom 60/81 (74.1%) patients recurred within two years and 21/81 (26.0%) recurred more than two years after surgery.